TCFL5 and disease of the tendon: First, even the in vitro and in vivo data support the therapeutic effects of cHA (50:50) + DEX and cHA (20:80) + DEX in tendinopathy, the downstream intracellular pathway of cHA + DEX responsible for modulation of apoptosis and senescence remained unclear.